Funding profile · Longevity and fibrosis therapeutics

Rejuvenation Technologies

One announced equity round, nine NIH award records, and no Form D anywhere in EDGAR. The federal money on record is now most of the capital this company can prove.

$10.6MSeed equity announced September 2023, led by Khosla Ventures
$7.60MSum of nine NIH award records, FY2020 to FY2026
$15.2MTotal raised, company-stated as of September 2023
0Form D notices filed by or naming the company in EDGAR

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2018 Y Combinator, Summer 2018 $1M, founder-stated Y Combinator Founder interview
Sep 2020 to Jul 2026 Federal grants $7,595,322 NIAAA, NHLBI, NCATS, NIGMS NIH RePORTER
Sep 2023 Seed $10.6M Khosla Ventures (lead), Shanda Ventures, Asymmetry Ventures, Merchant Adventures, Longevity Tech Fund, Y Combinator Company release
Sep 2026 Seed extension, open $10M target, more than $2M wired Not disclosed YC listing

What the filings show

SEC EDGAR · Form D · searched Sep 23, 2026

Full text search
Rejuvenation Technologies, restricted to form type D: 0 hits
Company search
No EDGAR registrant by that name has filed a Form D
Effect
No filed record of amount offered, amount sold, investor count or related persons
Reading
Consistent with a private placement done under Section 4(a)(2) rather than Regulation D

NIH RePORTER · nine award records · FY2020 to FY2026

AA028749
$2,757,252 across FY2020, FY2023 and FY2024, NIAAA, alcoholic hepatitis
TR005328
$2,149,782 across FY2024 to FY2026, NCATS, clinical translation tooling for intravenous RNA nanoparticles
AA033292
$2,063,303, FY2026, NIAAA, stated aim of reaching an IND by June 2028
GM153144
$324,998, FY2024, NIGMS, progenitor cell delivery
HL166034
$299,987, FY2022, NHLBI, pulmonary fibrosis
Principal investigator
John Ramunas on all nine records

Reading the filings

  1. There is no Form D to read.A Regulation D offering requires a notice within 15 days of the first sale. EDGAR holds none for this company, under its own name or any vehicle naming it. A priced seed sold to a handful of institutions can be closed under Section 4(a)(2) with no notice at all, so the absence does not mean the $10.6 million did not arrive. It does mean the usual filed checkpoints, investor count, amount sold against amount offered and the list of directors and officers, do not exist for this company.
  2. Federal money is now the larger provable line.The nine NIH records sum to $7,595,322 against $10.6 million of announced equity. Combined, that is $18,195,322, of which the grants are 42 percent. Of the NIH total, $6,396,189 was recorded in FY2024 or later, which is after the seed round closed.
  3. The company’s own total is three years stale.In September 2023 it reported $4.6 million in grants and $15.2 million raised in total. The grant figure on public record has since grown by about $3 million. No updated total has been published.
  4. One aggregator double counts the 2023 announcement.A startup data site lists $26.2 million across two rounds dated five days apart in September 2023, an $11 million seed and a $15.2 million grant. The company’s own release describes $10.6 million of equity plus $4.6 million of grants, totaling $15.2 million. The $26.2 million figure counts the same announcement twice.
  5. Headcount does not match the 2023 plan.The seed release said the money would bring on team members for scale-up manufacturing, clinical operations and research. The Y Combinator listing in September 2026 gives the team size as two. The company website carries eight staff biographies plus two scientific advisers. The two figures are not reconcilable from public sources.
  6. The largest single federal line is IND-directed.The NIAAA award that began on July 1, 2026 is worth $2,063,303 through June 2028 and is titled as advancing the telomere extension biologic to IND for alcohol-associated liver damage. That is the closest thing on public record to a clinical timetable.

Commercial signals

Signal Detail Source type
Clinical No study naming the company appears on ClinicalTrials.gov as of Sep 23, 2026. No IND clearance announced. An FDA INTERACT meeting is claimed but is not a public record. Public record
Pipeline TeloAT2 in pulmonary fibrosis listed as Phase I in Australia, 24 participants over 12 months. TeloHep in chronic liver disease, 32 participants, and TeloHSC in hematologic conditions, 12 participants, both listed as preclinical. Company-stated
Intellectual property One granted US patent assigned to the company, 12,721,818, dated Sep 1, 2026. The TERT mRNA patents are assigned to Stanford. The company claims 50 or more granted patents across 7 families. Claim exceeds US record
Revenue None disclosed. The company website invites contact to purchase reagents, which would be a research-tools line rather than product revenue. Company-stated
External validation An unaffiliated team at Hannover Medical School and Fraunhofer ITEM published hTERT modRNA results in human lung tissue in Aging Cell in November 2025. Independent

What to watch

  • A Form D for the seed extension, which would be the first filed disclosure of investor count and amounts.
  • Whether the extension is priced equity or convertible notes, which the notice would also reveal.
  • A trial registration, on the Australian registry for the stated Phase I or on ClinicalTrials.gov for any US study.
  • An IND announcement against the June 2028 end date of the NIAAA award.
  • Publication of the mouse and non-human primate data that the grant abstracts describe.

The Rejuvenation Technologies story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Ochre Bio: Shared investor: M Khosla Ventures. An Oxford company that designs RNA drugs and tests them in whole human donor livers kept alive on machines
  • SFA Therapeutics: Shared investor: Asymmetry Ventures. A Temple University spinout turning short chain fatty acids from the human gut into oral pills
  • Clear Gene: Shared investor: Asymmetry Ventures. An RNA test built to tell a surgeon whether the whole tumor came out
  • Digi-Prex: Shared investor: M Khosla Ventures. A WhatsApp-first subscription pharmacy for chronic disease patients in Hyderabad, funded in one of India’s largest 2019 seed rounds

Sources

  1. Public recordSEC EDGAR full text search, Rejuvenation Technologies, Form D, zero hitsSEC EDGAR · Sep 23, 2026
  2. Public recordNIH RePORTER records for projects AA028749, HL166034, TR005328, GM153144 and AA033292NIH · FY2020 to FY2026
  3. Public recordSBIR award listing 1R43GM153144-01SBIR.gov · Sep 15, 2024
  4. Public recordClinicalTrials.gov sponsor search, Rejuvenation Technologies, zero studiesClinicalTrials.gov API · Sep 23, 2026
  5. Public recordUS patent 12,721,818 and applications naming John RamunasJustia Patents · accessed Sep 23, 2026
  6. CompanyRejuvenation Technologies Raises $10.6M Seed Financing Led by Khosla VenturesBusiness Wire · Sep 6, 2023
  7. CompanyY Combinator company listing, seed extension and team sizeY Combinator · accessed Sep 23, 2026
  8. CompanyRejuvenation Technologies website, pipeline and team pagesAccessed Sep 23, 2026
  9. InterviewTelomere-boosting mRNA therapeutic turns back the aging clockLongevity.Technology · Sep 7, 2023
  10. IndependentRejuvenation Technologies: Funding, Team and InvestorsStartup Intros · accessed Sep 23, 2026
  11. IndependentTelomerase modRNA Offers a Novel RNA-Based Approach to Treat Human Pulmonary FibrosisAging Cell · Nov 2025

Compiled from SEC, NIH and other public records and published reports as of September 23, 2026. Form D notices report offerings under Regulation D; a company that raises under Section 4(a)(2) files none, so the absence of a notice is not evidence that no capital was raised. Healthcare Venture Capital Fund holds no position in Rejuvenation Technologies. This page is not an offer to sell or a recommendation to buy any security.